What is Spectral AI?
Headquartered in Dallas, Spectral AI is fundamentally transforming the landscape of wound care through its innovative DeepView System. By utilizing predictive AI, the company provides clinicians with immediate, objective assessments of burn wound healing potential, effectively Seeing the Unknown. This technology is designed to facilitate faster, more accurate treatment decisions, thereby improving patient outcomes while simultaneously driving down systemic healthcare costs. As a leader in the medical diagnostics sector, Spectral AI is transitioning from a research-heavy entity into a commercial-stage powerhouse, aiming to establish a new benchmark for value-based care in complex wound management.
How much funding has Spectral AI raised?
Spectral AI has raised a total of $104M across 9 funding rounds:
Debt
$350K
Multiple Rounds
$55.4M
Other Financing Round
$8.2M
Other Financing Round
$12.5M
Other Financing Round
$5M
Debt
$15M
Stock/Share Issuance
$7.6M
Debt (2020): $350K with participation from PPP
Other Financing Round (2021): $20.6M led by Biomedical Advanced Research and Development Authority
Stock Issuance/Offering (2021): $16M, investors not publicly disclosed
Other Financing Round (2021): $18.8M featuring US Biomedical Advanced Research and Development Authority
Other Financing Round (2022): $8.2M, investors not publicly disclosed
Other Financing Round (2024): $12.5M, investors not publicly disclosed
Other Financing Round (2024): $5M, investors not publicly disclosed
Debt (2025): $15M supported by AVENUE VENTURE OPPORTUNITIES FUND, LP, as Administrative Agent
Stock/Share Issuance (2025): $7.6M, investors not publicly disclosed
Key Investors in Spectral AI
AVENUE VENTURE OPPORTUNITIES FUND, LP
A New York-based investment firm specializing in venture debt and growth capital, providing strategic financial support to emerging technology companies.
Biomedical Advanced Research and Development Authority
A federal agency focused on the advanced research and development of medical countermeasures to protect the nation from health security threats.
PPP
Public-Private Partnership
What's next for Spectral AI?
With the recent influx of capital, Spectral AI is well-positioned to accelerate the commercial deployment of the DeepView System. The strategic roadmap likely involves expanding clinical validation studies and enhancing the underlying algorithm to support a wider array of wound care applications. As the company moves deeper into the enterprise-level growth phase, the focus will shift toward seamless integration into existing hospital workflows and securing broader regulatory and payer adoption. By maintaining its commitment to data-driven clinical decision support, Spectral AI is poised to capture significant market share in the high-growth medical technology sector.
See full Spectral AI company page
